按主题分类的文章 "KRAS"

1. 2025 KRAS Targeted Drug Progress
   发布于 2025年5月26日

   11
   In the field of cancer research, the KRAS gene has always occupied an important and unique position. For many years, due to its complex structure and functional characteristics, KRAS has been regarded as an "undruggable" target.
2. 2025 KRAS靶向药物进展
   发布于 2025年5月26日

   22
   在癌症研究领域，KRAS基因一直占据着重要且特殊的地位。多年来，由于其复杂的结构和功能特性，KRAS被视为 “不可成药” 靶点，然而随着科研技术的不断进步，针对KRAS的靶向治疗取得了突破性进展。
3. KRAS Inhibitors — The "Undruggable Target"? A Thing of the Past
   发布于 2025年5月19日

   6
   KRAS (Kirsten Rat Sarcoma Viral Oncogene Homolog) is a key member of the RAS family. Mutations in KRAS are among the most common oncogenic drivers in several malignancies, including non-small cell lung cancer (NSCLC), pancreatic cancer, and colorectal cancer. It is estimated that KRAS mutations ...
4. KRAS抑制剂——不可成药靶点”？已是历史
   发布于 2025年4月27日

   10
   KRAS（Kirsten Rat Sarcoma Viral Oncogene ...
5. 中药分子RA-V—协同KRAS G12C抑制的潜力因子 引言：靶向KRAS G12C的瓶颈与突破口
   发布于 2025年4月27日

   2
   KRAS G12C突变是结直肠癌（CRC）与非小细胞肺癌（NSCLC）等恶性肿瘤中常见的驱动突变之一。近年上市的KRAS G12C抑制剂如Adagrasib（MRTX849）和Sotorasib为患者提供了前所未有的治疗选择。
6. Traditional Chinese Medicine Molecule RA-V: A Potential Synergistic Factor in KRAS G12C Inhibition
   发布于 2025年4月27日

   2
   The KRAS G12C mutation is one of the common driver mutations in malignant tumors such as colorectal cancer (CRC) and non-small cell lung cancer (NSCLC). Recently approved KRAS G12C inhibitors like Adagrasib (MRTX849) and Sotorasib have provided unprecedented therapeutic options for patients.
7. GDC-1971: SHP2 Inhibitor Ushering in a New Era of Cancer Treatment
   发布于 2024年3月12日

   10
   In recent years, protein tyrosine phosphatase SHP2 has become a highly regarded research target in the field of oncology in mediating the RAS-driven MAPK signaling pathway. Its treatment methods are not limited to single drug use, but also can work together with KRAS inhibitors, showing good ...
8. GDC-1971——SHP2抑制剂引领癌症治疗新纪元
   发布于 2024年3月12日

   1
   近年来，蛋白酪氨酸磷酸酶SHP2在介导RAS驱动的MAPK信号转导过程中，已成为肿瘤学领域备受瞩目的研究靶点。其治疗方法不仅限于单药使用，还能与KRAS抑制剂共同协作，展现出良好的治疗潜力。